BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang W, Xia X, Chen K, Chen M, Meng Y, Lv D, Yang H. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling. Front Oncol 2021;11:665045. [PMID: 34168988 DOI: 10.3389/fonc.2021.665045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhaohui Tang, Yongjun Jiang, Sijuan Ding, Shaohui Jiang, Ruoting Tang, Pengfei Luo. miR-370 impacts the biological behavior of lung cancer cells by targeting the SMAD1 signaling pathway. Am J Transl Res 2022;14. [PMID: 36505312] [Reference Citation Analysis]
2 Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-01168-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Li W, Ye K, Li X, Liu X, Peng M, Chen F, Xiong W, Wang Y, Zhu L. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway. J Exp Clin Cancer Res 2022;41:250. [DOI: 10.1186/s13046-022-02460-9] [Reference Citation Analysis]
4 Chen C, Guo Y, Huang Q, wang B, Wang W, Niu J, Lou J, Xu J, Ren T, Huang Y, Guo W. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wang Y, Zhang J, Zhong LY, Huang SJ, Yu NN, Ouyang L, Niu YL, Chen JX, Lu CH, He QY. Hsa-miR-335 enhances cell migration and invasion in lung adenocarcinoma through targeting Copine-1. MedComm (2020) 2021;2:810-20. [PMID: 34977878 DOI: 10.1002/mco2.93] [Reference Citation Analysis]